TEST:

SeekInClarity®

"SeekIn Inc...today announced it has received authorization for five U.S. trademarks, further expanding its robust global intellectual property portfolio. The newly registered trademarks—SeekInCare® (blood-based pan-cancer early detection test), OncoSeek® (blood-based, low-cost multi-cancer early detection test), SeekInClarity® (blood-based pan-cancer treatment response monitoring test), LeukoPrint® (molecular karyotyping test for hematologic malignancies), and PanCanSeek® (precision diagnosis and therapeutic guidance for hematologic malignancies)—mark a significant milestone following successful trademark registrations in China and the European Union."

"SeekIn Inc...announced that it has obtained authorization to use five trademarks within the United States, including SeekInCare® (blood-based pan-cancer early detection test), OncoSeek® (blood-based low-cost multi-cancer early detection test), SeekInClarity® (blood-based pan-cancer treatment response monitoring test), LeukoPrint® (hematologic malignancies molecular karyotyping test), and PanCanSeek® (hematologic malignancies precision diagnosis and therapeutics guidance test). These acquisitions strengthen SeekIn Inc.'s intellectual property portfolio and open new avenues for the company to expand its reach and enhance its services within the United States."

The SeekInClarity-based molecular response predicts prompt treatment efficacy and serves as a valuable complementary tool for identifying non-responders among interim PET/CT response patients.

"SeekIn Inc...unveiled validation studies of multi-cancer early detection test, breakthrough lung cancer early detection test, and blood-based pan-cancer treatment response monitoring test at EUROMEDLAB 2025...1. Large-scale clinical validation of OncoSeek® multi-cancer early detection test...2. Lung cancer early detection with LungCanSeek®...3 SeekInClarity®: blood-based pan-cancer treatment response monitoring test"

On-treatment reduction of MTB correlates with patient survival and predicts efficacy in advance. Additionally, MTB status after two cycles of treatment serves as an independent prognostic factor for both PFS and OS.

"SeekIn Inc...announced today that it has obtained authorization to use eight trademarks within the European Union, including SeekInCare (the first-in-class blood-based pan-cancer early detection test), SeekInCure (the first-in-class blood-based pan-cancer recurrence monitoring test), SeekInClarity (pan-cancer treatment response monitoring), OncoSeek (low-cost early cancer detection test), LungCanSeek (lung cancer early detection test), LeukoPrint (the first-in-class leukemia sWGS CNA test), PanCanSeek (pan-cancer therapy guidance test)..."

"SeekIn Inc...announced a strategic collaboration with Oncolnv, a fully-owned affiliate of Inspire2Live, to expand the global accessibility of their multiple cancer detection tests and bridge disparities in cancer care. Starting this December, SeekIn's comprehensive range of cancer detection tests, namely OncoSeek, SeekInCare, SeekInCure and SeekInClarity will be distributed by Oncolnv in the following twelve countries: Belgium, Bulgaria, Costa Rica, Egypt, Ghana, Kenya, the Netherlands, Nigeria, Qatar, Singapore, Tanzania and UAE."

"SeekIn Inc...announces its participation in the prestigious ASCO Breakthrough Conference. The event takes place in Yokohama Japan on August 3-5, 2023...The second abstract presents a prospective study that utilizes SeekInClarity®, a pan-cancer, non-invasive efficacy detection technology, to evaluate treatment response and prognosis prediction in lymphoma patients."

"SeekIn Inc...announced the results of the pan-cancer/pan-indication treatment response monitoring test, SeekInClarity®, which were presented at the AMP 2022 Annual Meeting & Expo in Phoenix, Arizona, United States...study presents a strong demonstration that SeekInClarity can be considered an in vivo drug sensitivity test."

The dynamic change of MTB exhibited a good prognostic power of lymphoma. It challenged the status quo of employing imaging as a sole standard for evaluating early treatment response.

This prospective study demonstrated SeekInClarity, a non-invasive, multidimensional bloodbased assay, can promptly evaluate the treatment response of lymphoma patients, and showed an excellent correlation between MTB status and the clinical outcome. It challenged the status quo of employing imaging as a sole standard for evaluating early treatment response.

"SeekIn said...that it has received CE marking for its SeekInClarity Cancer Treatment Response Monitoring Kit...The Shenzhen, China-based biotech said that it is now ready to launch the kit in Europe and other countries that recognize the CE mark...The liquid biopsy assesses cancer treatment response through changes in circulating tumor DNA."